Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials
British Journal of Surgery · 06.09.2023 · 110 (10) · 1374-1380
DOI: 10.1093/bjs/znad210 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Surgery, online erschienen am 13.07.2023. Verfasst von Deesje Doppenberg und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Guidelines suggest that the serum carbohydrate antigen (CA19-9) level should be used when deciding on neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (hereafter referred to as pancreatic cancer). In patients with resectable pancreatic cancer, neoadjuvant therapy is advised when the CA19-9 level is ‘markedly elevated’. This study investigated the impact of baseline CA19-9 concentration on the treatment effect of neoadjuvant chemoradiotherapy (CRT) in patients with resectable and borderline resectable pancreatic cancers.
Methods
In this post hoc analysis, data were obtained from two RCTs that compared neoadjuvant CRT with upfront surgery in patients with resectable and borderline resectable pancreatic cancers. The effect of neoadjuvant treatment on overall survival was compared between patients with a serum CA19-9 level above or below 500 units/ml using the interaction test.
Results
Of 296 patients, 179 were eligible for analysis, 90 in the neoadjuvant CRT group and 89 in the upfront surgery group. Neoadjuvant CRT was associated with superior overall survival (HR 0.67, 95 per cent c.i. 0.48 to 0.94; P = 0.019). Among 127 patients (70, 9 per cent) with a low CA19-9 level, median overall survival was 23.5 months with neoadjuvant CRT and 16.3 months with upfront surgery (HR 0.63, 0.42 to 0.93). For 52 patients (29 per cent) with a high CA19-9 level, median overall survival was 15.5 months with neoadjuvant CRT and 12.9 months with upfront surgery (HR 0.82, 0.45 to 1.49). The interaction test for CA19-9 level exceeding 500 units/ml on the treatment effect of neoadjuvant CRT was not significant (P = 0.501).
Conclusion
Baseline serum CA19-9 level defined as either high or low has prognostic value, but was not associated with the treatment effect of neoadjuvant CRT in patients with resectable and borderline resectable pancreatic cancers, in contrast with current guideline advice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands.
- Cancer Centre Amsterdam, Amsterdam, the Netherlands.
- Department of Radiation Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands.
- Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
- Department of Surgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.
- Department of Surgery, Leiden University Medical Centre, Leiden, the Netherlands.
ORCID-Profile: Jacob L van Dam, Olivier R Busch, Vincent E de Meijer, Stijn van Roessel, Judith de Vos-Geelen, Marc G Besselink, Bas Groot Koerkamp
Zitieren
APA
Doppenberg, D., van Dam, J. L., Han, Y., Bonsing, B. A., Busch, O. R., Festen, S., van der Harst, E., de Hingh, I. H., Homs, M. Y. V., Kwon, W., Lee, M., Lips, D. J., de Meijer, V. E., Molenaar, I. Q., Nuyttens, J. J., Patijn, G. A., van Roessel, S., van der Schelling, G. P., Suker, M., …, & Dutch Pancreatic Cancer Group (2023). Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials. British Journal of Surgery, 110(10), 1374-1380. https://doi.org/10.1093/bjs/znad210
Vancouver
Doppenberg D, van Dam JL, Han Y, Bonsing BA, Busch OR, Festen S, et al. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials. British Journal of Surgery. 2023;110(10):1374-1380. doi:10.1093/bjs/znad210
BibTeX
@article{Doppenberg2023,
author = {Doppenberg, Deesje and van Dam, Jacob L and Han, Youngmin and Bonsing, Bert A and Busch, Olivier R and Festen, Sebastiaan and van der Harst, Erwin and de Hingh, Ignace H and Homs, Marjolein Y V and Kwon, Wooil and Lee, Mirang and Lips, Daan J and de Meijer, Vincent E and Molenaar, I Quintus and Nuyttens, Joost J and Patijn, Gijs A and van Roessel, Stijn and van der Schelling, George P and Suker, Mustafa and Versteijne, Eva and de Vos-Geelen, Judith and Wilmink, Johanna W and van Eijck, Casper H J and van Tienhoven, Geertjan and Jang, Jin-Young and Besselink, Marc G and Groot Koerkamp, Bas and Dutch Pancreatic Cancer Group, Dutch Pancreatic Cancer Group},
title = {Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials},
journal = {British Journal of Surgery},
year = {2023},
volume = {110},
number = {10},
pages = {1374--1380},
doi = {10.1093/bjs/znad210}
}
EUVIMED